Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syros Pharmaceuticals
(NQ:
SYRS
)
2.265
-0.255 (-10.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Syros Pharmaceuticals
< Previous
1
2
3
4
Next >
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
October 31, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 24, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
September 04, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
August 27, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
August 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
August 20, 2024
From
The Schall Law Firm
Via
Business Wire
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
August 12, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
July 31, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
July 24, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
June 13, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in Upcoming Investor Conferences
May 07, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
May 07, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
April 09, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
March 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
March 25, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
March 20, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
January 08, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 19, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
December 06, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in Upcoming Investor Conferences
November 21, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 14, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
October 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 08, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
August 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.